CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Regulation FD Disclosure
Item 7.01
Executive management of Conatus Pharmaceuticals Inc. will be presenting an updated corporate presentation at various upcoming meetings with securities analysts, investors and others beginning on April 8, 2019. The corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall expressly be set forth by specific reference in such filing.
| Item 7.01. | Financial Statements and Exhibits. |
Conatus Pharmaceuticals Inc. Exhibit
EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 NASDAQ CNAT Company Update Striving to improve human health April 2,…
To view the full exhibit click here
About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
